TY - JOUR
T1 - Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy
T2 - Not All AIDS-Defining Conditions Are Created Equal
AU - Antiretroviral Therapy Cohort Collaboration (ART-CC)
AU - Mocroft, Amanda
AU - Sterne, Jonathan A.C.
AU - Egger, Matthias
AU - May, Margaret
AU - Grabar, Sophie
AU - Furrer, Hansjakob
AU - Sabin, Caroline
AU - Fatkenheuer, Gerd
AU - Justice, Amy
AU - Reiss, Peter
AU - D'Arminio Monforte, Antonella
AU - Gill, John
AU - Hogg, Robert
AU - Bonnet, Fabrice
AU - Kitahata, Mari
AU - Staszewski, Schlomo
AU - Casabona, Jordi
AU - Harris, Ross
AU - Saag, Michael
AU - Chêne, Geneviève
AU - Costagliola, Dominique
AU - Dabis, François
AU - De Wolf, Frank
AU - Ledergerber, Bruno
AU - Phillips, Andrew
AU - Weller, Ian
AU - Sterna, Jonathan
AU - Abgrall, S.
AU - Barin, F.
AU - Bentata, M.
AU - Billaud, E.
AU - Boué, F.
AU - Burty, C.
AU - Cabié, A.
AU - Cotte, L.
AU - De Truchis, P.
AU - Duval, X.
AU - Duvivier, C.
AU - Enel, P.
AU - Fredouille-Heripret, L.
AU - Gasnault, J.
AU - Gaud, C.
AU - Gilquin, J.
AU - Katlama, C.
AU - Khuong, M. A.
AU - Lang, J. M.
AU - Lascaux, A. S.
AU - Launay, O.
AU - Mahamat, A.
AU - Huitema, A. D.R.
N1 - Publisher Copyright:
© 2009 by the Infectious Diseases Society of America. All rights reserved.
PY - 2009/4/15
Y1 - 2009/4/15
N2 - Background. The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. Methods. We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy. ADEs that occurred in <50 patients were grouped together to form a "rare ADEs" category. Results. During a median follow-up period of 43 months (interquartile range, 19-70 months), 2880 ADEs were diagnosed in 2262 patients; 1146 patients died. The most common ADEs were esophageal candidiasis (in 360 patients), Pneumocystis jiroveci pneumonia (320 patients), and Kaposi sarcoma (308 patients). The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70- 14.92). Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (non-Hodgkin's lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55-9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76- 3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08-2.00]). Conclusions. In the combination antiretroviral therapy era, mortality rates subsequent to an ADE depend on the specific diagnosis. The proposed classification of ADEs may be useful in clinical end point trials, prognostic studies, and patient management.
AB - Background. The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. Methods. We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy. ADEs that occurred in <50 patients were grouped together to form a "rare ADEs" category. Results. During a median follow-up period of 43 months (interquartile range, 19-70 months), 2880 ADEs were diagnosed in 2262 patients; 1146 patients died. The most common ADEs were esophageal candidiasis (in 360 patients), Pneumocystis jiroveci pneumonia (320 patients), and Kaposi sarcoma (308 patients). The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70- 14.92). Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (non-Hodgkin's lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55-9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76- 3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08-2.00]). Conclusions. In the combination antiretroviral therapy era, mortality rates subsequent to an ADE depend on the specific diagnosis. The proposed classification of ADEs may be useful in clinical end point trials, prognostic studies, and patient management.
UR - http://www.scopus.com/inward/record.url?scp=63649147273&partnerID=8YFLogxK
U2 - 10.1086/597468
DO - 10.1086/597468
M3 - Article
C2 - 19275498
AN - SCOPUS:63649147273
SN - 1537-6591
VL - 48
SP - 1138
EP - 1151
JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
IS - 8
ER -